NRx Deploys First FDA-Cleared Robotic TMS System

On SEP 11 2026, ZRX dropped by 0.4% within 24 hours to reach $0.1003, ZRX dropped by 5.28% within 7 days, rose by 5.79% within 1 month, and dropped by 28.57% within 1 year.

Strategic Expansion of Neuropsychiatric Infrastructure

NRx Pharmaceuticals, Inc. announced that its subsidiary, HOPE Therapeutics, Inc., is positioned to become the first Interventional Psychiatry organization to deploy Zeta Surgical’s newly FDA-cleared Zeta TMS Robotic System. This development marks a significant transition from concept to clinical reality for the company’s integrated neuropsychiatric platform. Clinical staff are currently undergoing training at Zeta Surgical’s headquarters in Boston ahead of the system's deployment at HOPE’s Florida clinics.

The Zeta TMS Robotic System utilizes AI-driven software to adjust the TMS coil in real time with submillimeter precision. This technology builds upon the Zeta TMS Navigation System, which HOPE previously implemented as the first commercial site in the United States to deploy such navigation capabilities earlier in the summer. The robotic system is designed to bring robotic precision and advanced image guidance to TMS treatment, potentially improving the ability of clinicians to consistently target specific areas of the brain.

Enhancing Precision and Clinical Outcomes

Jonathan Javitt, M.D., M.P.H., Chairman and CEO of NRx Pharmaceuticals and HOPE Therapeutics, emphasized the clinical advantages of this deployment. He noted that the difference between precise, repeatable targeting and approximation is critical for patients and clinicians. With this new capability, clinicians can deliver neurosurgical-grade precision to every patient in every session. This advancement removes the dependency on patients remaining perfectly still or technicians manually holding the coil with exact precision.

This technological upgrade directly supports the SPARC-TMS trial, a project involving NRX-101 and robotic TMS. NRx is initiating this project for the military in partnership with Harvard McLean Hospital. The goal of these initiatives is to achieve measurable, rapid, and durable remission from depression. The deployment represents another step in NRx’s broader strategy of combining advanced TMS technology, clinical treatment infrastructure, pharmaceutical development, and emerging precision-treatment capabilities.

Commercial and Regulatory Progress

NRx Pharmaceuticals is approaching a potentially important period characterized by multiple converging catalysts. The company is advancing toward potential 2026 commercialization while managing FDA regulatory progress, commercial manufacturing, and the expansion of HOPE Therapeutics. Additionally, the company is progressing with NRX-101 development and a potential DARPA-funded Phase 2/3 program.

To engage with the investment community regarding these developments, NRx CEO Jonathan Javitt participated in a scheduled appearance at the Cantor Global Healthcare Conference on September 11. The company also prepared for further engagement at the H.C. Wainwright 28th Annual Global Investment Conference on September 14. These events provided a platform to discuss the integration of the new robotic technology with the company’s existing pharmaceutical and clinical assets.

Platform Integration and Future Outlook

The acquisition and deployment of Zeta Surgical’s technology add a new dimension to NRx’s operational narrative. Rather than focusing solely on pharmaceutical development, the company is constructing an integrated platform that leverages advanced hardware to enhance therapeutic outcomes. The successful training and subsequent deployment in Florida serve as a validation of this strategy.

The move underscores NRx’s commitment to advancing interventional psychiatry through technological innovation. By combining FDA-cleared robotic systems with proprietary pharmaceutical trials, the company aims to establish a comprehensive approach to treating neuropsychiatric conditions. The ongoing training of clinical staff and the preparation for deployment in Florida indicate that the company is actively moving toward the practical application of these advanced tools in real-world clinical settings.